Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s share price shot up 2.8% during trading on Friday . The company traded as high as $2.23 and last traded at $2.22, with a volume of 62,929 shares traded. The stock had previously closed at $2.16.

Several equities research analysts have issued reports on CNAT shares. FBR & Co reissued a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Monday, April 18th. Brean Capital reissued a “buy” rating and set a $7.00 target price (down previously from $13.00) on shares of Conatus Pharmaceuticals in a research note on Monday, May 9th. Finally, Roth Capital started coverage on Conatus Pharmaceuticals in a research note on Friday, July 1st. They set a “buy” rating for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. Conatus Pharmaceuticals has an average rating of “Buy” and a consensus price target of $9.66.

The firm’s 50 day moving average price is $2.14 and its 200 day moving average price is $2.21. The stock’s market capitalization is $47.42 million.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.35) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.35). During the same period last year, the firm posted ($0.38) earnings per share. Equities analysts predict that Conatus Pharmaceuticals Inc. will post ($1.53) EPS for the current fiscal year.

An institutional investor recently raised its position in Conatus Pharmaceuticals stock. Jennison Associates boosted its position in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by 0.6% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 659,067 shares of the biotechnology company’s stock after buying an additional 3,983 shares during the period. Jennison Associates owned approximately 3.32% of Conatus Pharmaceuticals worth $2,933,000 as of its most recent filing with the SEC.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.